Mythic Therapeutics Faces An Acid Test
Emerging Company Profile: Efficacy data on the young group’s first pH-engineered antibody-drug conjugate could come next year, and potential partners will be watching.
Emerging Company Profile: Efficacy data on the young group’s first pH-engineered antibody-drug conjugate could come next year, and potential partners will be watching.